PMID- 23439790
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20130227
LR  - 20220408
IS  - 0974-620X (Print)
IS  - 0974-7842 (Electronic)
IS  - 0974-620X (Linking)
VI  - 5
IP  - 3
DP  - 2012 Sep
TI  - Ranibizumab in patients with dense cataract and proliferative diabetic 
      retinopathy with rubeosis.
PG  - 161-5
LID - 10.4103/0974-620X.106099 [doi]
AB  - BACKGROUND: To evaluate the safety of ranibizumab as a surgical adjunct during 
      cataract surgery in patients with proliferative diabetic retinopathy (PDR) with 
      rubeosis, and to evaluate the efficacy and adverse effects of ranibizumab in 
      treating PDR with rubeosis. MATERIALS AND METHODS: Three intravitreal injections 
      of 0.5 mg ranibizumab were administered on day-1, months-1 and -2 with cataract 
      surgery 6-16 days after first injection. Retreatments with ranibizumab injections 
      and pan-retinal photocoagulation (PRP) were given if recurrence or persistence of 
      PDR was noted between months-3 and -11. Safety observation visits occurred at 
      months-12, -18 and -24. Primary end points were incidence and severity of adverse 
      events (AEs) that were related to both cataract surgery and treatment of PDR with 
      rubeosis through month -12. RESULTS: Of six patients screened, four (mean age 
      61.3 years) were enrolled. No AEs were noted with either cataract surgery or 
      treatment of PDR. Neovascularization of iris (NVI) promptly regressed by 4 days 
      after first ranibizumab injection, prior to cataract surgery in three of four 
      patients (one had significantly regressed NVI by post-injection day-3 visit); NVI 
      was not noted in any patient at 2 weeks after first ranibizumab injection. 
      Recurrence of rubeosis or NVA after 3 monthly injections was not observed in any. 
      At month-12, PDR was not present when assessed clinically and by fluorescein 
      angiogram (FA). Only one patient developed neovascularization of disc and 
      neovascularization elsewhere and required retreatments at months-5 and -9. 
      CONCLUSIONS: Multiple intravitreal injections of ranibizumab may be a safe, 
      effective treatment adjunct for PDR and diabetes-related rubeosis.
FAU - Tu, Yufei
AU  - Tu Y
AD  - The Institute of Ophthalmology and Visual Science, New Jersey Medical School, 90 
      Bergen Street Suite 6100, Newark, New Jersey, USA.
FAU - Fay, Catherine
AU  - Fay C
FAU - Guo, Suqin
AU  - Guo S
FAU - Zarbin, Marco A
AU  - Zarbin MA
FAU - Marcus, Edward
AU  - Marcus E
FAU - Bhagat, Neelakshi
AU  - Bhagat N
LA  - eng
PT  - Journal Article
PL  - India
TA  - Oman J Ophthalmol
JT  - Oman journal of ophthalmology
JID - 101519430
PMC - PMC3574511
OTO - NOTNLM
OT  - Cataract
OT  - diabetic retinopathy
OT  - neovascularization
OT  - ranibizumab
OT  - rubeosis iridis
COIS- Conflicting Interest: No.
EDAT- 2013/02/27 06:00
MHDA- 2013/02/27 06:01
PMCR- 2012/09/01
CRDT- 2013/02/27 06:00
PHST- 2013/02/27 06:00 [entrez]
PHST- 2013/02/27 06:00 [pubmed]
PHST- 2013/02/27 06:01 [medline]
PHST- 2012/09/01 00:00 [pmc-release]
AID - OJO-5-161 [pii]
AID - 10.4103/0974-620X.106099 [doi]
PST - ppublish
SO  - Oman J Ophthalmol. 2012 Sep;5(3):161-5. doi: 10.4103/0974-620X.106099.